A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs TTP 399 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Simplici-T1; SimpliciT1
- Sponsors vTv Therapeutics LLC
- 22 Jun 2018 According to a vTv Therapeutics media release, phase II portion of this trial is ongoing.
- 22 Jun 2018 Data from this trial will be presented at the American Diabetes Association's 78th Scientific Sessions 2018, according to a vTv Therapeutics media release.
- 14 Jun 2018 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.